<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3203">
  <stage>Registered</stage>
  <submitdate>19/06/2011</submitdate>
  <approvaldate>19/06/2011</approvaldate>
  <nctid>NCT01377831</nctid>
  <trial_identification>
    <studytitle>Study of Ketamine Administered Intravenously and by Sublingual Wafer</studytitle>
    <scientifictitle>An Open Label, Two Way Crossover Study to Evaluate the Bioavailability and Clinical Tolerability of a Novel Sublingual Wafer Formulation of Ketamine in Healthy Male Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>KET001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain</healthcondition>
  </conditions>
  <interventions>
    <interventions />
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bioavailability of a single 25 mg dose of sublingual (SL) ketamine - Bioavailability determined by evaluation and comparison of PK variables following SL and IV administration.</outcome>
      <timepoint>24 hours post-dose for two dosing periods, which were separated by 7 days.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>General clinical tolerability and safety - Determined by using a range of objective and subjective parameters.</outcome>
      <timepoint>24 hours post-dose for two dosing periods, which were separated by 7 days.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of disintegration - Measured the apparent rate of disintegration of a single 25 mg sublingual wafer formulation of ketamine.</outcome>
      <timepoint>5 minutes post-dose</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Adult males aged 18-65 years.

          2. Good general health without clinically significant renal, hepatic, cardiac or
             respiratory disease, as determined by the Principal Investigator.

          3. Good general mental health as determined by scores on the Symptom Checklist-90-R
             (SCL-90-R®), a screening instrument which evaluates a broad range of psychological
             problems and symptoms of psychopathology.

          4. Agree to and be capable of signing an Informed Consent Form.

          5. Have suitable venous access for blood sampling.

          6. BMI within the range of 19-30 kg/m2.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Renal impairment as evidenced by estimated creatinine clearance (CrCl), measured by
             the Cockcroft-Gault method, of less than 90 mL/min.

          2. Have a laboratory value at the Screening Visit that is outside the normal range,
             unless it is judged by the Investigator as not clinically significant after
             appropriate evaluation.

          3. A score of more than two standard deviations from the mean on any of the key nine
             scales in the SCL-90-R ®

          4. Any medical condition that in the opinion of the Investigator may adversely impact on
             the participant's ability to complete the study, including but not limited to:

               -  History of cerebral trauma or stroke

               -  History of seizure or epilepsy

               -  Hyperthyroidism

               -  Recent clinically significant URTI (within two weeks of Day 1) or respiratory
                  infection

               -  History of Myocardial Infarction or clinically significant cardiac disease
                  including cardiac arrhythmia.

               -  Poorly controlled hypertension - as assessed by the Principal Investigator.

               -  Clinically significant history of asthma requiring regular supportive or
                  preventative therapy (childhood asthma that has resolved &gt;5 years previously may
                  be suitable for inclusion at the discretion of the Investigator.

               -  Glaucoma

          5. Plasma AST, ALT and ALP tests in excess of 1.5 times the upper limit of normal.

          6. History of severe allergic or anaphylactic drug-related reactions.

          7. History of hypersensitivity to ketamine or any of its excipients.

          8. Current (within the last six months) clinically significant psychiatric disorder
             including anxiety, psychosis or depression.

          9. Concurrent use of other medication on a regular or daily basis including but not
             limited to, theophylline, benzodiazepines, thyroxine, sedatives or anti-anxiolytics.

         10. Participation in another clinical trial of an investigational agent within 30 days of
             study entry.

         11. Known history of past or present infection with hepatitis C virus (HCV), hepatitis B
             or human immunodeficiency virus (HIV).

         12. Clinically significant abnormal ECG (12-lead) at the screening visit or prior to
             dosing on Day 1, as determined by the Investigator.

         13. Participants who have a marked prolongation of the QT corrected (QTc) interval (i.e.,
             repeated demonstration of a QTc &gt;430 msec for males) at screening or prior to dosing
             on Day 1 in either study period will not be allowed to continue in the study.

         14. Significant history of illicit drug or alcohol use or abuse (as determined by the
             Principal Investigator).

         15. Any alcohol use within 24 hours prior to dosing on Day 1 in each of the study periods.

         16. Unwillingness or inability to comply with the requirements of this protocol, including
             the presence of any condition (physical, mental, or social) that is likely to affect
             the participant returning for follow-up visits on schedule.

         17. Blood donation (1 unit or more) within 1 month prior to the screening visit.

         18. Current or previous tobacco user (within 12 months prior to Day 1) .

         19. Planned surgical procedure requiring general anaesthesia during the study period and
             within two weeks of study completion</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>8</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Pain and Anaesthesia Research Clinic (PARC), Royal Adelaide Hospital - Adelaide</hospital>
    <postcode>5000 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>iX Biopharma Ltd.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine the rate and extent of of absorption of racemic ketamine from sublingual wafer</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01377831</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pual Rolan</name>
      <address>Pain and Anaesthesia Research Clinic - PARC</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>